Check each claim against its experiments, reported results, scope, and stated limitations.Know what the science actually supports before you trust the answer.
Press Enter ↵ to start review
Explore by Goal
"Just like a single cell, the character of our lives is determined not by our genes but by our responses to the environmental signals that propel life."
- Bruce H. Lipton
Quick Answer
Copied
Core claim (from the paper text you provided)
HLA-B61 subtypes (B’4002 vs B’4006) are distinguished by two amino-acid substitutions at residues 95 (Leu→Trp) and 97 (Ser→Thr), while HLA-B60 (B*40012) vs HLA-B61 (B’4006) differ by four substitutions on the β sheet (res. 11, 12, 95, 97) and five substitutions on the α2 helix (res. 143, 147, 177, 178, 180), with the authors hypothesizing that α2-helix residues primarily drive alloantibody discrimination in this allo-specificity context.
Source: Kawaguchi et al., Human Immunology (1993) DOI: 10.1016/0198-8859(93)90125-K
Inline evidence:
Long Answer
Paper Review: Structural analysis of HLA-B40 epitopes
Primary source analyzed: Kawaguchi et al., 1993. DOI: 10.1016/0198-8859(93)90125-K. GenBank submissions: M95530 (HLA-B*40012) and M95531 (HLA-B’4006).
1) What the paper does (grounded in the text you provided)
Goal
The paper aims to clarify structural (sequence) differences among HLA-B40-related alleles/specificities, focusing on how substitutions relate to alloantibody specificity—particularly the discrimination of HLA-B60 vs HLA-B61 subtypes.
Methods (as stated)
Constructs: genomic libraries in λ phage from peripheral blood lymphocytes of two Japanese donors with specified HLA phenotypes, hybridized with an HLA-B7 cDNA probe.
Cloning/verification: restriction enzyme patterns on multiple enzymes to identify putative alleles.
Expression: transfect clones into Hmy2CIR (C1R) cells; select high expressers using flow cytometry with W6/32 anti-HLA class I mAb and SFR-8B6 anti-Bw6 mAb.
Functional typing readout: complement-dependent cytotoxicity against HLA alloantisera; clones assigned as HLA-B60 vs HLA-B61 based on which alloantisera kill transfected C1R cells.
Sequence determination: exons sequenced by dideoxy/chain termination method (Sequenase mentioned in text).
2) Visual: where the key substitutions sit (β sheet vs α2 helix)
From the paper’s stated counts
For B*40012 vs B’4006, the paper states 4 substitutions on the β sheet (residues 11, 12, 95, 97) and 5 substitutions on the α2 helix (residues 143, 147, 177, 178, 180).
The paper states that B’4002 and B’4006 share an epitope for alloantibodies specific for HLA-B61, yet two amino-acid substitutions at residues 95 and 97 discriminate two B61 subtypes.
Residue → substitution (as stated)
95
Leu → Trp (codon: CTC → TGG)
97
Ser → Thr (codon: AGC → ACG)
4) Reasoning and interpretation (with explicit uncertainty)
What is supported directly vs inferred
Supported by the paper’s own experimental logic: genotype/allele cloning + sequencing, and assignment of allo-specificity through complement-dependent cytotoxicity patterns, are reported as the basis for identifying B60 vs B61 clones and for mapping differences to residues.
Supported but not quantified in your provided text: localization of substitutions to “β sheet” vs “α2 helix” is asserted using a structural model context (figures referenced).
Speculative hypothesis in the text: residues on the α2 helix may provide discriminating alloantibody epitopes because the β-sheet residues “seem hardly to affect binding” (wording from the provided abstract/discussion text). This is a mechanistic suggestion, not a demonstrated epitope map in the provided excerpt.
Genotype-to-protein specificity pipeline: the paper combines cloning/sequencing with functional alloantibody readout in C1R transfectants (mAb selection + cytotoxicity alloantisera typing), rather than relying only on sequence comparisons.
Specific residue-level narrative: it identifies a small set of substitutions (notably 95 and 97) associated with subtype discrimination, keeping the hypothesis chemically/structurally constrained.
Red flags / limitations (only what we can responsibly infer from the provided text)
Small donor sampling: sequencing/allele discovery is reported from two Japanese individuals with specified HLA phenotypes; the paper itself notes distribution in other populations is not known.
Epitope mapping is indirect: while the paper speculates residues form alloantibody epitopes (β-sheet vs α2 helix), the provided excerpt does not include direct binding/structural epitope mapping (e.g., systematic mutagenesis validating each candidate residue’s effect on alloantibody binding).
Alloantisera complexity: complement-dependent cytotoxicity is an aggregate functional readout; alloantibody panels may vary in epitope specificity and potency, which can compress mechanistic resolution into “patterns” rather than a clean causal map.
Model dependence: structural localization uses referenced 3D structural context; without the full figure details here, residue-to-pocket interpretations (e.g., “facing pockets C and E”) remain hypothesis-level.
6) Reproducibility check (what you can reproduce from the provided text)
Sequence availability: the paper states GenBank accession numbers for HLA-B*40012 and HLA-B’4006 (M95530, M95531), which supports external re-use of the allele sequences.
Assay workflow is described: genomic library screening → transfection → mAb selection → cytotoxicity assays → sequence comparison.
But: the provided excerpt does not include full experimental parameters (e.g., exact cytotoxicity scoring thresholds beyond the categories shown, detailed primer sequences table contents, or all mapping details); reproducibility would require the complete manuscript figures/tables and exact lab conditions.
7) Practical takeaway
Most actionable residue candidates (as per the text you provided)
If one were to design follow-up alloantibody epitope experiments around this paper’s claims, the most prominent candidates it highlights are residues 95 and 97 (subtype discrimination within B61 subtypes) and the α2-helix residues 177–180 (suggested discriminating epitope contributors between HLA-B60 and HLA-B61), while the β-sheet residues are described as less influential for alloantibody binding.
8) Go deeper with author-focused reviews
Feedback:
Updated: April 19, 2026
BGPT Paper Review
Study Novelty
80%
Novelty is moderately high because it reports additional Japanese sequencing of HLA-B61 variants and frames a structural substitution-based hypothesis for alloantibody discrimination (residues 95/97; β sheet vs α2 helix), rather than only re-stating prior antigen classifications.
Scientific Quality
70%
Quality is judged as moderate-high because the study links cloned/sequenced alleles to alloantibody cytotoxicity typing in transfected C1R cells and highlights specific residue differences. Main limitations (from the provided text) are small donor sampling, indirect epitope inference from functional sera patterns, and dependence on structural interpretation without direct quantitative epitope mapping in the excerpt. No clear conflict-of-interest statements are provided in your excerpt; assay readout is inherently aggregate (cytotoxicity) and may compress mechanism.
Study Generality
40%
Findings are allele- and context-specific (HLA-B40 split into B60/B61 subtypes; Japanese cohort). While structurally informative for HLA class I epitope logic, the generalization to other populations/allele families is limited by the paper’s own stated unknown distribution across populations.
Study Usefulness
60%
Usefulness is moderate: it provides concrete residue candidates and accession numbers for specific alleles that can support downstream comparative/hypothesis-driven studies on alloantibody specificity, but it does not, in the provided excerpt, deliver a definitive causal epitope map or broadly generalizable rule-set.
Study Reproducibility
60%
Reproducibility is partially supported by reported GenBank accession numbers (M95530, M95531) and a described workflow (library screening, transfection into C1R, selection by mAbs, cytotoxicity assay, and exon sequencing). However, the provided excerpt does not include all experimental granularities required for full end-to-end replication.
Explanatory Depth
50%
The paper provides a residue-structured explanatory hypothesis (β sheet vs α2 helix; 95/97 for B61 subtypes; α2 residues for alloantibody discrimination) but remains speculative in mechanistic details in the excerpt because direct epitope validation is not shown.
Parses the paper’s stated residue differences, builds an interpretable substitution-region feature vector (β-sheet vs α2-helix), and outputs a ranked candidate residue list for follow-up epitope testing.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
The hypothesis that β-sheet residues (11/12/95/97) are broadly irrelevant to alloantibody binding is less persuasive as a default if future direct binding assays show strong β-sheet contact; current evidence in the excerpt is inferential (“seem hardly to affect”), not causally resolved.
The idea that subtype discrimination is solely determined by primary sequence identity at residues 95/97 is less optimal if structural-pocket orientation varies with other nearby residues not explicitly highlighted in the excerpt; the paper itself suggests pocket-facing context, implying indirect effects could dominate.
Explore by Goal
Quick Answer
Long Answer
Top Data Sources
Ask a Follow-Up
Key Insight
Keep Exploring
Analysis 
Hypothesis Graveyard
Potential Experiments
Discussion